Quantcast

Latest Multiple Myeloma Research Consortium Stories

2011-06-25 00:00:30

S. 3988/A. 6233 will ensure that health plans already providing insurance coverage for chemotherapy will provide equal coverage for both IV/injected and oral therapies. The bill will be sent to the governor shortly. New York, NY (PRWEB) June 24, 2011 The New York Assembly voted unanimously 6/22/11 to pass S. 3988/A. 6233, a bill that will eliminate the disparity in insurance coverage between oral and intravenous chemotherapy therapies, ensuring that all cancer patients in the state have...

2011-05-10 06:30:00

CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a Phase I study of REOLYSIN(®) alone in patients with relapsed multiple myeloma. The NCI is sponsoring the trial under its Clinical Trials Agreement with...

2011-04-28 07:00:00

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France. "The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma. Data from several studies...

2010-12-13 08:27:00

RYE, N.Y., Dec. 13, 2010 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has appointed Jennifer Katritos, CPA, as vice president of finance, the company announced. She joined Curemark in July, 2009 as director of finance. Katritos oversees Curemark's financial function, responsible for financial planning and reporting and risk analysis. During her 20-year career, Katritos has held a variety of financial positions,...

2010-12-09 09:32:00

In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec. 9, 2010 /PRNewswire-USNewswire/ -- A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose...

b87993d1b33f05fb0360ed2a92fae0481
2010-12-09 10:45:43

In early results, all participants responded to treatment with limited side effects A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib...

2010-12-07 08:12:00

In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the sixth paragraph, first sentence, should read "In a subset analysis of patients who were refractory to bortezomib in their last line of therapy (n=128), carfilzomib achieved an ORR of 19 percent and CBR of 31 percent" rather than " In a subset analysis of patients who were...

2010-12-07 06:30:00

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after...

2010-07-26 06:00:00

EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. In an independent review of the data, carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of 7.4 months in...

2010-06-05 16:30:00

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable patients who had not been previously...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related